New atopic dermatitis drug candidate GS101 put to the test against dupixent®
NCT ID NCT07411755
First seen Feb 20, 2026 · Last updated May 16, 2026 · Updated 9 times
Summary
This early-stage study compares a new drug, GS101, to the approved treatment Dupixent® for atopic dermatitis (eczema). It involves 294 healthy adult volunteers in China to see how the body processes each drug, their safety, and any immune reactions. The goal is to check if GS101 works similarly to Dupixent® before testing it in patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215004, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.